RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

Benzinga · 2d ago
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and lowers the price target from $451 to $450.